-
Innovation Ranking
NewInnovation Ranking – Smurfit Kappa Group plc
Smurfit Kappa Group Plc (Smurfit) is a provider of paper packaging solutions. It manufactures, distributes and markets corrugated containers, container boards and other paper-based packaging products. The company’s product offerings include graphic and solid boards, paper bags, protective packaging products, container boards, kraftliners, corrugated and packaging products. It also offers recovered papers, packaging machinery, pulp, testliners, preprinted liners, retail packaging, postal packaging, point of sale displays, seedlings, and bag-in-box. The company also provides services such as packaging design and consultancy...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Denosumab Biosimilar in Giant Cell Tumor Of Bone
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Denosumab Biosimilar in Giant Cell Tumor Of Bone report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Denosumab Biosimilar in Giant Cell Tumor Of Bone...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Trastuzumab Biosimilar in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Biosimilar in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab Biosimilar in Adenocarcinoma Of The Gastroesophageal Junction...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trastuzumab Biosimilar in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Biosimilar in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anifrolumab in Vitiligo
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anifrolumab in Vitiligo report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anifrolumab in Vitiligo Drug Details: Anifrolumab (Saphnelo) is a immunoglobulin G1 kappa (IgG1?)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Margetuximab in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Margetuximab in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Margetuximab in Head And Neck Squamous Cell...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Trastuzumab Biosimilar in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Biosimilar in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab Biosimilar in Metastatic Breast Cancer Drug Details: Trastuzumab biosimilar...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Trastuzumab Biosimilar in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Biosimilar in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab Biosimilar in Gastric Cancer Drug Details: Trastuzumab biosimilar is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Margetuximab in Gallbladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Margetuximab in Gallbladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Margetuximab in Gallbladder Cancer Drug Details: Margetuximab (Margenza) is a Fc-engineered human...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anifrolumab in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anifrolumab in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anifrolumab in Systemic Sclerosis (Scleroderma) Drug Details: Anifrolumab (Saphnelo) is a...